Objective: The early diagnosis of chronic organ rejection after lung transplantation (LTx) is currently hampered by the lack of reliable diagnostic markers. The present study aims to establish the procedure of gene expression profiling in bronchial epithelial cells for the identification of candidate genes that might prove useful in the early diagnosis. Methods: Twenty-three patients who underwent lung transplantations were investigated at a time point when no clinical signs of bronchiolitis obliterans syndrome (BOS) were apparent. Bronchial epithelial cells were obtained by bronchial brushing. Gene expression profiles were determined using a human whole-genome cDNA microarray (Stanford Faculty, Stanford, CA, USA). Results: Unsupervised hierarchical cluster analysis revealed that the samples from LTx patients can be clearly distinguished from the comparison group. We also found that the samples from LTx patients with the same underlying disease do not form major clusters of gene expression pattern. Using biostatistical analysis, 'haemoglobin beta', expressed by alveolar type II and Clara cells, and CD99, involved in inflammatory processes, were identified comparing lung transplantation and comparison group. Conclusions: Thus, global expression analyses of bronchial epithelial cells might be a new approach to identify diagnostic markers, especially if patients with LTx are monitored sequentially and if patients with and without BOS are compared. #
Introduction
Lung transplantation (LTx) still provides a real therapeutic option for patients with end-stage lung disease, with good early and mid-term results. Major indications for lung transplantation include pulmonary fibrosis, obstructive lung disease, cystic fibrosis, primary pulmonary hypertension, secondary pulmonary hypertension (primarily Eisenmenger's syndrome) and re-transplantation. Hitherto, chronic graft dysfunction represented a major obstacle for long-term benefit of this procedure [1] .
A significant cause of morbidity and mortality in lung transplant recipients is the bronchiolitis obliterans syndrome (BOS). BOS is associated with chronic inflammation and fibrosis of bronchi, characterised histologically in its early stages by infiltration of the bronchiolar epithelium with lymphocytes, plasma cells and histiocytes. Moreover, it is known that acute rejection of the lung allograft occurs in 30-50% of lung transplant recipients and is strongly associated with the development of BOS. The diagnosis of BOS is warranted only when all other potential aetiologies for the airflow reduction (e.g., infection, bronchial stenosis and acute rejection) have been excluded since reliable diagnostic markers are lacking [2, 3] .
To date, the most important parameter for the diagnosis of BOS is based on clinical findings with a significant reduction in maximal mid-expiratory flow (MMEF25-75) or a reduction in a patient's forced expiratory volume in 1 s (FEV1) compared to a previously established baseline value [4, 5] .
Detection of BOS at an earlier stage is urgently required in order to adopt changes in a patient's immunosuppressive regimen, which might be more efficient when airway damage is still minimal. In this context, the identification of differentially expressed genes using microarray technologies could help to better understand the pathogenesis of the disease.
In this pilot study, bronchial epithelial cell (BEC) specimens were obtained by bronchial brushing from 23 patients, who had undergone lung transplantation but did not show any clinical signs of BOS. Whole-genome cDNA microarray analysis and hierarchical clustering showed that patients with lung transplantation with the same underlying disease do not form major clusters of gene expression pattern, which will greatly facilitate further analyses to identify diagnostic markers for BOS. The identification of 153 differentially expressed genes in comparison to analogy samples obtained from healthy individuals without any signs of lung disease shows that this high throughput approach might be a valuable contribution for the identification of important genes in BECs, which might indicate the beginning process of BOS.
Materials and methods

Study subjects
All subjects enrolled gave their informed consent to participate in this study. Approval from the Ethics Committee of Hannover Medical School was given on 28 October 2003. Twenty-three samples were obtained from patients 8-15 months after lung transplantation. Of the 23 patients, 10 were affected by cystic fibrosis, six had lung emphysema, two had idiopathic pulmonary fibrosis, three showed alpha-1-PI deficiency, one secondary pulmonary fibrosis and one patient was affected by graft-vs-host reaction (summarised in Table 1 ). The patient group consisted of 23 patients who had undergone lung transplantation. They were investigated at a time point, that is, 8-15 months after LTx, when they did not show any clinical signs of BOS. The diagnosis of BOS followed the guidelines of the ISHLT (2002). The control group consisted of six healthy persons without any signs of lung disease.
Bronchial brush specimens
To obtain cells from the airway mucosa, a sheathed bronchial specimen brush (Product No. 7839237; Boston Scientific, Boston, MA, USA) was advanced through the operating channel of the bronchoscope, positioned in a segmental bronchus and pushed gently back and forth 10 times. After retracting the tip into the protective sheath, the brush was removed. In order to harvest a sufficient number of BECs, this procedure was performed in four different segmental lobes. The cells were gently removed from the brush by light shaking in saline solution. The suspension was pooled and aliquots were used for total cell counts and differential. Total cell counts were measured by a Coulter counter (Coulter Electronics, Hialeah, FL, USA). A cell differential of each sample was obtained from slide preparations, which were stained with May-Grünwald-Giemsa. The remaining suspension was stored at À80 8C.
RNA extraction
Extraction of RNA from cells stored at À80 8C was performed according to the Trizol method (Invitrogen, Karlsruhe, Germany), followed by the use of RNeasy Mini Kit (Qiagen, Hilden, Germany). The quality and integrity of the total RNA were determined on a bioanalyser (Agilent Technologies, Böblingen, Germany). From total RNA (1 mg obtained from 10 6 cells), mRNA was isolated and amplified (MessageAmp aRNA kit, Ambion, Huntingdon, UK).
cDNA microarray analysis
We used two-colour, whole-genome, cDNA microarray analysis-a method in which RNA from cases and controls are co-hybridised against a reference RNA. The cDNA microarray experiments were carried out as previously described [6, 7] . As probes, patient RNA and control RNA (labelled with CY3) were co-hybridised with the reference RNA (labelled with CY5). The reference DNA was obtained from a pool of healthy persons. After microarray experiments, the fluorescence intensities of Cy5 and Cy3 were measured on a GenePix 4000 scanner (Axon Instruments, Foster City, CA, USA) and analysed using GenePix Pro 4.1 software (Axon Instruments).
Biomathematical analysis of data
The image analysis was performed using a dual-laser scanner and the GenePix Pro 4.1 imaging software (GenePix 4000 A; Axon Instruments, Union City, CA, USA). Microarray data were then uploaded to the Stanford Microarray Database (http://genome-www5.stanford.edu/index.shtml). Each array was normalised using the web-based tool provided by the Stanford Functional Genomics Facility. This software package allows the extraction of sample intensities or ratios at each printed cDNA location in a given microarray scan. Areas of the microarray or spots that exhibited obvious damage were excluded from subsequent analysis. Single spots were only considered as well measured and included in the further investigation if the mean fluorescent intensity of Cy5 and Cy3 was !1.5-fold the local background, and if the regression correlation was !0.6. The well-measured genes were subsequently 'mean centred' (i.e., reported for each gene relative to the mean ratio across all samples, rather than relative to the reference). Normalised and log-transformed expression data served as input for significance analysis of microarrays (SAM) [8] with the relevant standard parameters. Using this method, genes with statistically significant changes in expression are identified by assimilating a set of gene-specific t-tests. A score is assigned to each gene based on the change in gene expression relative to the standard deviation of repeated measurements. For genes with scores greater than an adjustable threshold, SAM uses permutations of the repeated measurements to estimate the percentage of genes identified by chance, the false discovery rate (FDR). The FDRs varied between 0.0 and 0.371. All software packages used for SAM were available from the Stanford microarray database (http://genome-www5.stanford.edu/index.shtml).
Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for relative quantification
In a total volume of 50 ml, 416 ng of total RNA were reverse transcribed by M-MuLV reverse transcriptase using random hexamer primers (RevertAid First Strand cDNA synthesis kit; Fermentas, St-Leon-Rot, Germany). Each cDNA sample (5 ml) was used for the analysis of 'globin beta' and CD99 expression. This expression was performed using a LightCycler device (version 2.0, Roche, Penzberg, Germany). Primers and probes were synthesised by Tib MolBiol (Berlin, Germany). Detailed PCR conditions and primer sequences for all genes used are shown in Table 2 . TATA-box binding protein (TBP) was used as internal control gene. For calibration, a pool of RNA from five healthy individuals was used as reference. The master mix for the PCR was combined using the DNA Master Hybridisation Kit (Roche, Penzberg, Germany). Relative quantification of gene expression was determined according to the DD-CT method using the LightCycler software, version 4.05. All samples were analysed in triplicate.
Results
A total of 23 BEC samples and six from healthy subjects obtained by bronchial brushing were analysed. As shown in Table 1 , about 1-2 million cells were harvested from one brushing. All BEC samples showed a high purity with a percentage of epithelial cells of more than 90% in nearly all cases.
Microarray analysis
For gene expression analyses from BECs, high-quality results are important [9] . The most important requirement is a sufficient amount of good RNA. In most instances, 60 mg RNA were isolated from bronchial brushes. Quality control using the Agilent Bioanalyser (Agilent Technologies, Böblin-gen, Germany) showed that the 28s RNA and 18s RNA peaks are clearly visible, and there were no or only minimal signs of degradation. Furthermore, also after amplification, mRNA was of sufficient quality for gene expression profiling (Fig. 1) . The mean length of amplified fragments was 900-1000 bp.
This study aimed to define a baseline gene expression profile of BECs from patients with lung transplantation at the time point after LTx where no clinical signs of BOS were recognised. Microarray analysis using whole-genome cDNA arrays containing 43 000 spots were performed on 23 samples obtained from patients 8-15 months after lung transplantation and compared to the reference, a pool of RNA from five healthy individuals without any signs of lung disease. In addition, microarray analyses were performed on six comparison samples obtained from healthy indivi- 
duals without any signs of lung disease compared to the reference. About 3005 cDNA clones with expression differing the most between the samples from patients and from healthy subjects compared to the reference were selected. To organise the results for visual display and for further analysis, we used a hierarchical clustering algorithm based on Pearson's correlation (centred) coefficients to group the genes, as well as the samples, on the basis of similarity in their expression pattern. This analysis revealed that almost all samples from patients clustered together, as did those of the controls. With only a few exceptions, samples from patients with lung transplantation could therefore be clearly distinguished from the controls by biostatistical analysis (Fig. 2) . Moreover, we investigated whether other underlying lung diseases influenced the gene expression pattern after lung transplantation, that is, whether samples from lung transplantation patients with the same underlying disease cluster together and show similar expression signatures. As shown in Fig. 2 , hierarchical cluster analysis did not divide the samples into disease-related subgroups, for example, cystic fibrosis, lung emphysema and alpha-1-PI deficiency, but presented all samples in one cluster of the tree.
Analysis of gene expression by SAM
As a second step, the 3005 most differentially expressed genes were selected for additional bioinformatic analysis. SAM [8] was applied to identify genes that were statistically significantly different between the two groups of samples. SAM revealed 153 genes that were differentially expressed in the group of patients with lung transplantation vs the group of six comparison samples from healthy subjects. Of the 153 genes, 13 transcripts were up-regulated and 140 were downregulated in samples from lung transplantation patients compared to those from the healthy subjects (Fig. 3) . Among the up-regulated genes were HBB, CD99, HBA2, HBE1, ALDH3B2, HNRPH1, H1F0, PALMD and PSAP (Table 3) .
Real-time RT-PCR for relative quantification of globin beta and CD99
Real-time RT-PCR of the genes globin beta and CD99 was used for validation of the microarray results and to confirm the diagnostic relevance of the differentially expressed genes. These genes should be up-regulated in the samples of the patients with lung transplantation compared to the samples from healthy subjects. In the quantitative PCR, the expression of globin beta showed an increased expression in all selected samples of the patients compared to the healthy subjects. In contrast, globin beta was reduced in all selected samples from healthy subjects (Fig. 4a) . Studying the valid target for interference with cutaneous inflammatory processes, CD99 was up-regulated in all selected samples of the patients with lung transplantation as against the samples from healthy subjects, which showed a reduced expression, with only one exception (Fig. 4b) .
Discussion
This is the first microarray analysis on lung transplant recipients in which BECs were used as a source for RNA. Therefore, the first step was to establish a protocol for the isolation of sufficient quality and amount of RNA obtained from BECs, extracted by sheathed bronchial specimen brush, for high-quality cDNA microarray analysis. We have shown that bronchial brushes give a relatively pure fraction of epithelial cells and that high-quality RNA could be isolated from these cells. We next aimed to show that the cDNA microarray analysis of BECs obtained from patients after lung transplantation and from persons without lung transplantation is a reliable, reproducible and powerful tool for the identification of genes and gene expression patterns indicative of inflammatory processes in the context of BOS.
Data from the Lung Allograft Rejection Gene expression Observational (LARGO) study provides compelling evidence that profiling gene expression in peripheral blood can detect organ rejection in lung transplant patients. Data from the study show that the immune responses of lung transplant recipients can result in novel molecular signatures identifying the absence or presence of acute cellular rejection [10, 11] .
BOS is associated with chronic inflammation and fibrosis of bronchi, characterised histologically in its early stages by infiltration of the bronchiolar epithelium with lymphocytes, plasma cells and histiocytes. Therefore, the aim of the present study was to establish the procedure of gene expression profiling in BECs for the identification of genes de-regulated in bronchial epithelia to open up new insights for a better understanding of the molecular pathogenesis.
Gimino et al. [12] were the first to show that microarray analysis in lung transplant recipients is a reliable and reproducible tool for the analysis of acute lung rejection using bronchioalveolar lavage fluid (BALF) cells. They found 135 genes which were up-regulated in the acute rejection group. Among these most important up-regulated genes, 31 were identified as being immune response genes important in acute rejection; 19 were identified as being, up to now, not known to be involved in acute rejection; six genes were involved in the process of apoptosis; five genes were important in transcriptional regulation; and 10 genes were involved in cell signalling. In this study of Gimino et al. [12] , cells were taken which were isolated by centrifugation of BALF from patients who were transplanted 30 days earlier. BALF consists of a mixture of BECs and immunologically active cells such as macrophages, neutrophils and lymphocytes, whereas bronchial brush specimens, as used in our study, contained a relatively pure cell population of >90% BECs. This may explain why, to the best of our knowledge, no overlapping genes were identified in the two studies. We used unsupervised cluster analysis of the microarray data, based on the 3005 gene elements exhibiting the highest differential expression between samples from patients with lung transplantation and healthy controls vs reference. The clustering algorithm, based on Pearson's correlation (centred), collocates all healthy subjects together as expected, with one exception only (S06) (Fig. 2) and, moreover, arranges all the other samples from patients with lung transplantation within the same branch. This suggests that, on the one hand, the method adequately detects differences in gene expression between transplanted and nontransplanted patients and, on the other hand, the differences in gene expression within one group are not so high that separate clusters are formed. Thus, at this time point, 8-15 months after LTx, the underlying lung diseases did not influence the gene expression pattern, since patients with the same underlying disease, for example, cystic fibrosis, lung emphysema or 1PI deficiency did not cluster into major groups of gene expression. The results also indicate that the gene expression profile of BECs does not seem to be influenced by considerable numbers of recipient-derived fibroblasts or other immunoreactive cells like T lymphocytes [13] .
In order to prove the reliability of our method, we selected the 3005 most varying features for subsequent SAM [8] . We were interested in the most discriminative and statistically significant genes between patients with lung transplantation and the comparison group of healthy subjects which may be indicative of inflammation or injury at the lung at this early time point after transplantation. Some of the nine named genes whose expression positively correlated with patients with lung transplantation are known to be involved in defence mechanisms, two of which -HBB and CD99 -should be discussed in more detail. The additional investigation of the expression of globin beta and CD99 RNA by real-time PCR has shown that the expression was considerably increased in all selected samples of the patients with lung transplantation.
Newton et al. [14] found that 'haemoglobin beta (HBB)' is expressed by alveolar type II (ATII) cells and Clara cells, the primary producers of pulmonary surfactant [14] . The endogenous synthesis of 'haemoglobin' in alveolar epithelial cells suggests that, in the lung, haemoglobin may have unidentified functions other than oxygen transport. Moreover, 'haemoglobin' gene expression in non-erythroid cells has been previously reported in activated macrophages from adult mice and lens cells [15] . CD99, which is a transmembrane protein encoded by the MIC-2 gene, is expressed in most leukocytes. Interestingly, CD99 is a valid target for interference with cutaneous inflammatory processes [16] . It has to be validated in a larger patient cohort whether these genes can be used as diagnostic and prognostic markers for early diagnosis of inflammatory processes in the context of BOS and as a rationale for early therapeutic interventions.
In conclusion, this established method is a new method to characterise processes after lung transplantation. Follow-up investigation analyses of patients with lung transplantation are under way to identify genes de-regulated in those patients developing BOS. 
